Xenon Pharmaceuticals Inc. research snapshot
XENE AI stock analysis currently reads Xenon Pharmaceuticals as a clinical-stage neurology biotech trading at $62.67 as of the July 31, 2026 close, about 14% below its 52-week high of $72.66. The company has no approved products and generated only $7.50 million in collaboration revenue in FY2025, with R&D expenses of $301 million driving a GAAP net loss of $346 million. The thesis rests on azetukalner, a KV7 potassium channel opener. In April 2026 the company reported positive Phase 3 X-TOLE2 topline data in focal onset seizures, showing a 53.2% median reduction in monthly seizure frequency at the 25 mg dose versus 10.4% for placebo, and plans to submit an FDA NDA in Q3 2026. Market capitalization was about $6.06 billion at the data cutoff, and the AI rating is cautiously constructive on the Phase 3 validation and $1.34 billion cash runway into 2029, while noting that most of the pipeline still faces binary readouts. This page is informational research, not investment advice.
Current price
$62.67
Market cap
About $6.06 billion using 96.67 million common shares
AI score
55 / 100
Rating
Clinical-stage neurology biotech with positive Phase 3 X-TOLE2 data, a planned Q3 2026 NDA submission, and a $1.34 billion cash position
Trend status
Pulled back about 14% from the 52-week high with high binary-outcome risk
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Xenon is a clinical-stage biotech focused on ion channel modulation for CNS disorders. It has no approved products and only modest collaboration revenue. The validated Phase 3 X-TOLE2 result in focal epilepsy upgrades the quality of the lead program, but the company still has no commercial revenue. | Low |
| Moat | The commercial moat remains unproven. Xenon owns a proprietary ion channel discovery platform and patents on azetukalner, but durability only becomes testable if the drug reaches the market and competes against established antiseizure medicines. | Low |
| Management | Leadership is under President and CEO Ian Mortimer, with CFO Tucker Kelly, CMO Chris Kenney, and COO Matthew Ronsheim. Capital allocation has been disciplined, including the Q1 2026 equity raise of about $838 million that extended the cash runway into 2029. Recent insider activity has included routine inducement equity grants to new employees. | Medium |
| Financial trend | Net loss widened from about -$234 million in 2024 to -$346 million in 2025 as R&D spending accelerated to $301 million. Cash and marketable securities totaled about $1.34 billion at March 31, 2026, with no debt, funding operations into 2029. The Q1 2026 equity offering of about $838 million materially strengthened the balance sheet. | High |
| Valuation | At $62.67, the enterprise value is about $4.72 billion net of the $1.34 billion cash position. P/B is about 4.53x. With no product revenue, conventional PE or EV/Sales metrics are not meaningful. The valuation reflects the probability-weighted NPV of azetukalner across its epilepsy, depression, and pain programs. | Medium |
| Technical trend | The stock is in a pullback from the $72.66 52-week high, trading near $62.67 with a July 31 intraday low around $62.56. It remains well above its 52-week low of $30.00, with the 200-day moving average estimated well below price. Momentum has cooled after the earlier advance. | Medium |
| Risk level | Binary clinical and regulatory risk remains the primary concern. Risks include X-TOLE3 and depression program outcomes, FDA approval decisions on the planned NDA, commercialization competition from established epilepsy drugs, shareholder dilution, and the inherent uncertainty of pre-revenue biotech investing. | High |
| AI confidence | High confidence for balance sheet, cash, and financial statement data plus the Phase 3 X-TOLE2 statistics. Medium for regulatory and NDA timing. Low for probability-of-success estimates across earlier-stage programs. | High data confidence |
| Investment certainty | Lower than AI data confidence because value still depends on binary regulatory and clinical outcomes. A successful NDA and positive MDD data would support a much higher valuation, while a setback in X-TOLE3, an FDA rejection, or weak depression data could compress it sharply despite the strong cash position. | Medium-low |
XENE AI stock forecast
The XENE AI stock forecast uses scenario ranges based on azetukalner regulatory and clinical outcomes, not a precise price prediction. Xenon has no product revenue, so conventional PE-based valuation does not apply. The scenarios reflect different outcomes for the planned NDA submission, the remaining Phase 3 trials in focal and generalized epilepsy, and the MDD and bipolar depression programs.
$90 to $120
More likely if the NDA filing in Q3 2026 proceeds smoothly, the FDA accepts and approves azetukalner for focal epilepsy, X-TOLE3 confirms the efficacy profile, and the MDD X-NOVA2 data expected in H1 2027 is positive. A successful launch trajectory toward $2 billion or more in peak sales would support a market cap re-rating toward $9-12 billion.
$60 to $90
More likely if the NDA submission and approval process takes longer than expected, X-TOLE3 confirms efficacy with questions about label scope, or the market waits for MDD and bipolar depression data before assigning value. Valuation would trade near the current range as the company builds a commercial franchise.
$20 to $50
More likely if X-TOLE3 misses endpoints, the FDA requires additional trials or rejects the NDA, safety signals emerge, or depression program results disappoint. The cash-adjusted floor is estimated near $14 per share based on the $1.34 billion cash position, but a broad pipeline failure would likely compress the stock toward that floor.
XENE AI technical analysis
XENE AI technical analysis uses the $62.67 July 31 close as the reference price. The stock is in a pullback from the $72.66 52-week high, down about 14% from the high but still up about 109% from the $30.00 52-week low. The medium-term trend remains positive with price above the estimated 200-day moving average, but momentum has cooled in the recent consolidation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $62.67 | Google Finance listed the closing price as of July 31, 2026. This is the reference quote for the page. |
| Near support | $60 to $62 | The $60-62 zone has held as support during the recent pullback. A close below $60 would suggest a deeper correction toward the 50-day moving average zone. |
| Near resistance | $68 to $70 | The $68-70 zone marks the breakdown area from the July high and is the first resistance. A reclaim would open a test of the $72.66 52-week high. |
| 50-day moving average | Estimated $63 to $66 | The 50-day MA is estimated near the current price after the pullback, which means price is right at a decision point for the short-term trend. |
| 200-day moving average | Estimated $52 to $58 | The 200-day MA is estimated below the current price, indicating a positive medium-term trend. A close below this zone would be a significant warning signal. |
| Momentum | RSI estimated 45 to 55 | RSI in the neutral zone suggests momentum has cooled after the pullback from the high. Watch for RSI above 60 with price back above $68 for renewed strength. |
| Volume | 1.57 million 20-day average | Trading volume is moderate relative to the float. Volume spikes around NDA and clinical data events will be the primary drivers of significant price moves. |
| Volatility | Beta 0.61 | A beta below 1.0 suggests XENE has tended to move less than the market, but this understates event-driven risk. Clinical and regulatory catalysts can produce extreme single-day moves. |
| Invalidation | Close below $55 | A decisive break below the $55 zone would invalidate the positive medium-term trend and suggest the pullback has become a broader decline toward the 52-week low area. |
XENE AI trading strategy
The XENE AI trading strategy is a rules-based framework for research. It is not a personalized buy, sell, or hold recommendation. Traders should pair any setup with position sizing, stop logic, NDA and clinical trial catalyst dates, and biotech sector data.
The medium-term trend is positive within a $30-72 range. A trend-following approach would hold while price stays above the estimated 50-day moving average and would add on a breakout back above $68-70 with above-average volume confirming the move.
If price breaks below $60 on above-average volume, the pullback is deepening. A close below $55 would invalidate the medium-term uptrend.
XENE is a catalyst-driven biotech where the primary events are the Q3 2026 NDA submission, FDA decision timelines, X-TOLE3 and depression program data, and the August 6, 2026 Q2 earnings and business update. Position sizing should account for the possibility of large moves on any announcement.
The highest risk is holding through a negative clinical or regulatory announcement. Position size should never exceed what the trader is willing to lose entirely. Consider using options strategies or stop-losses ahead of catalyst dates.
Track NDA submission timing and FDA milestones, X-TOLE3 topline, X-NOVA2 MDD data expected in H1 2027, X-ACKT and X-CEED progress, cash burn, equity dilution events, and competitor epilepsy and depression drug data. The $1.34 billion cash runway into 2029 provides a long fundamental clock.
The highest risks are regulatory rejection or delay, binary Phase 3 outcomes in remaining programs, safety signal emergence, dilution through equity offerings, and competitive pressure in epilepsy and depression.
Investment research summary
Xenon is funded by capital markets to develop azetukalner, a KV7 potassium channel opener, for epilepsy, major depressive disorder, and bipolar depression. The company has no approved products and generated only $7.5 million in collaboration revenue in FY2025. Investors fund R&D spending of about $300 million per year in exchange for a potential multi-billion dollar neurology franchise if the pipeline succeeds.
Xenon owns a proprietary ion channel discovery platform and patents covering azetukalner and related compounds. Positive Phase 3 X-TOLE2 data validates the mechanism, but the commercial moat is unproven until the drug reaches the market and competes against established antiseizure and depression medicines.
The thesis fails if X-TOLE3 misses endpoints, the FDA rejects or delays the planned NDA, depression program data disappoints, safety findings limit the label, or the company needs to raise dilutive capital at a low price. The most dangerous scenario is a broad clinical or regulatory setback that compresses the stock toward its cash-adjusted floor near $14 per share.
President and CEO Ian Mortimer leads a team that includes CFO Tucker Kelly, CMO Chris Kenney, and COO Matthew Ronsheim. The team has executed well on clinical development and capital raising, including the Q1 2026 equity offering of about $838 million that funds operations into 2029. Key-person risk exists around the clinical, regulatory, and commercial leadership.
Epilepsy and major depressive disorder are large markets with significant unmet need. About one-third of epilepsy patients are drug-resistant, and azetukalner would be the only potassium channel opener among antiseizure medications if approved. The CNS channel modulation trend is favorable, but the regulatory bar is high and competition in epilepsy and depression is intensifying.
At about $4.72 billion enterprise value net of the $1.34 billion cash position, XENE is pricing in a meaningful probability that azetukalner succeeds commercially. The cash-adjusted floor of about $14 per share provides some downside protection, but a broad pipeline failure would likely compress the valuation toward near-cash levels, representing significant downside from current levels.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Reference price | $62.67 closing price, July 31, 2026 | Google Finance XENE quote | August 3, 2026 |
| Market capitalization | About $6.06 billion, verified as $62.67 x 96.67 million shares using financial_rigor.py with 0.03% deviation | Google Finance and MarketBeat shares outstanding | August 3, 2026 |
| FY2025 revenue | $7.50 million, entirely collaboration revenue | MarketBeat XENE annual income statement | August 3, 2026 |
| FY2025 net loss | GAAP net loss of $346 million, widened from about -$234 million in FY2024 | MarketBeat XENE annual income statement | August 3, 2026 |
| Q1 2026 net loss | $102.30 million net loss on zero product revenue | Google Finance XENE quarterly income statement | August 3, 2026 |
| R&D expense FY2025 | $301 million, up from $210 million in FY2024 | MarketBeat XENE annual income statement | August 3, 2026 |
| Cash and marketable securities (Q1 2026) | $546 million cash plus $549 million short-term investments plus $245 million long-term investments = $1.34 billion total | MarketBeat XENE quarterly balance sheet | August 3, 2026 |
| Debt | No debt. Total liabilities of $49 million at March 31, 2026 | MarketBeat XENE balance sheet | August 3, 2026 |
| Phase 3 X-TOLE2 topline | Azetukalner 25 mg produced a -53.2% median percent change in monthly seizures vs -10.4% for placebo (p<0.0001); NDA submission planned for Q3 2026 | Xenon Q1 2026 business update via StockTitan | August 3, 2026 |
| Analyst consensus | 11 analysts: 11 Buy. Average target $75.77, high $86.00, low $63.00 | Google Finance XENE analyst ratings | August 3, 2026 |
| Valuation ratios | P/B about 4.53x, P/E N/A (negative earnings). Enterprise value about $4.72 billion net of cash | financial_rigor.py valuation verification | August 3, 2026 |
This XENE AI stock analysis is an informational research tool only. It is not investment advice, financial advice, or a recommendation to buy, sell, or hold Xenon Pharmaceuticals shares. Forecast scenarios are based on available data at the stated cutoff and can be wrong. Clinical-stage biotech investing carries binary risk. Past performance does not guarantee future results.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
